Trade Ultragenyx - RARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 43.18 |
| Open | 44.75 |
| 1-Year Change | 5.44% |
| Day's Range | 42.7 - 44.77 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| May 3, 2024 | 42.70 | -0.53 | -1.23% | 43.23 | 45.84 | 42.58 |
| May 2, 2024 | 43.18 | -0.39 | -0.90% | 43.57 | 43.96 | 42.64 |
| May 1, 2024 | 43.22 | 0.76 | 1.79% | 42.46 | 43.99 | 42.20 |
| Apr 30, 2024 | 42.49 | -0.97 | -2.23% | 43.46 | 44.18 | 42.47 |
| Apr 29, 2024 | 43.98 | -0.40 | -0.90% | 44.38 | 45.17 | 43.88 |
| Apr 26, 2024 | 44.16 | 0.20 | 0.45% | 43.96 | 44.47 | 43.69 |
| Apr 25, 2024 | 43.80 | 0.44 | 1.01% | 43.36 | 43.88 | 42.68 |
| Apr 24, 2024 | 44.24 | -0.67 | -1.49% | 44.91 | 45.49 | 43.49 |
| Apr 23, 2024 | 45.02 | 1.98 | 4.60% | 43.04 | 45.50 | 43.04 |
| Apr 22, 2024 | 43.64 | 0.47 | 1.09% | 43.17 | 44.36 | 42.36 |
| Apr 19, 2024 | 42.27 | -0.48 | -1.12% | 42.75 | 43.61 | 41.02 |
| Apr 18, 2024 | 43.31 | -0.61 | -1.39% | 43.92 | 44.72 | 43.20 |
| Apr 17, 2024 | 44.01 | 1.85 | 4.39% | 42.16 | 44.54 | 42.16 |
| Apr 16, 2024 | 42.24 | 0.27 | 0.64% | 41.97 | 44.11 | 41.97 |
| Apr 15, 2024 | 42.82 | -1.49 | -3.36% | 44.31 | 44.31 | 41.96 |
| Apr 12, 2024 | 46.92 | -2.99 | -5.99% | 49.91 | 50.50 | 46.73 |
| Apr 11, 2024 | 50.66 | -1.30 | -2.50% | 51.96 | 52.22 | 50.29 |
| Apr 10, 2024 | 51.57 | 2.31 | 4.69% | 49.26 | 51.62 | 49.26 |
| Apr 9, 2024 | 50.51 | 0.42 | 0.84% | 50.09 | 51.14 | 50.09 |
| Apr 8, 2024 | 50.19 | -0.11 | -0.22% | 50.30 | 51.07 | 49.09 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ultragenyx Company profile
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.
Equity composition
Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.
| Industry: | Bio Therapeutic Drugs |
60 Leveroni Ct
NOVATO
CALIFORNIA 94949
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com